西妥昔单抗联合化疗治疗晚期非小细胞肺癌疗效观察.DOCVIP

西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察 斯晓燕，张 力 （100730 北京，中国医学科学院中国协和医科大学北京协和医院呼吸内科） [摘要] 目的 研究西妥昔单抗联合化疗一线治疗非小细胞肺癌（non-small cell lung cancer ,NSCLC）的疗效。 方法 回顾性分析北京协和医院呼吸科2008年11月至2012年4月使用西妥昔单抗联合化疗的20例非小细胞肺癌患者的临床资料，进行疗效和安全性评估。所有患者签署了知情同意书，并同意提供临床资料。 结果 截至分析之日尚有8例患者仍存活，最长1例Cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer Si Xiaoyan, Zhang Li (Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, 100730, China.) [Abstract] Objective To evaluate the safety and efficacy of cetuximab combined with chemotherapy as first line therapy in patients with non-small cell lung cancer (NSCLC). Methods A retrospective analysis of clinical data was conducted in 20 patients who were given cetuximab combined with chemotherapy as first line therapy in our department between November 2008 and April 2012. All patients signed the informed consent, and consented to offer clinical information. Results Eight patients were alive up to the time of our analysis, and the longest survival was 39.8 months. The objective response rate (ORR), disease control rate (DCR), median progression free survival (PFS), and estimated least median overall survival (OS) were 50.0%, 70.0%, 8.6 months and 10.9 months, respectively. The common adverse events included skin toxicity (15, 75.0%), alanine aminotransferase elevation (3, 15.0%), hematological toxicity (2, 10.0%), allergy (1, 5.0%) and fever (1, 5.0%). Conclusion Cetuximab combined with chemotherapy as first line therapy for patients with NSCLC has promising ORR, DCR, and PFS. Serious adverse events are of low incidence and quite controllable. We should search predictive factors for selecting appropriate patients. [Key words] cetuximab；non-small cell lung cancer；chemotherapy Corresponding author: Zhang Li, E-mail：zhangli1026@ E-mail：zhangli1026@ 表皮生长因子受体（epidermal growth factor receptor，EGFR）是一种具有